Masseron Adrien, AlAyadhi Demah, Blanc Jacques, Fuchsmann Carine, Lapierre Ariane, Ceruse Philippe, Philouze Pierre
Département de cancérologie cervicofaciale, Groupement hospitalier Nord, hospices civils de Lyon, 103, grande-rue de la Croix-Rousse, 69004, Lyon, France; Université Lyon 1, 69000, Lyon, France.
Département de cancérologie cervicofaciale, Groupement hospitalier Nord, hospices civils de Lyon, 103, grande-rue de la Croix-Rousse, 69004, Lyon, France; Université Lyon 1, 69000, Lyon, France; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, 11426, Riyadh, Kingdom of Saudi Arabia.
Eur J Surg Oncol. 2025 Jul;51(7):109755. doi: 10.1016/j.ejso.2025.109755. Epub 2025 Mar 7.
The aim of this study was to compare the overall survival and prognostic factors of patients ≥80 years old with those of patients aged 70-79 years who were diagnosed with head and neck squamous cell carcinoma.
A retrospective study was conducted between 2013 and 2021. Patients were divided into two groups: group-1, aged ≥80 years, and group-2, aged between 70 and 79 years; all patients were diagnosed with squamous cell carcinoma of the head and neck and treated with curative intent.
A total of 346 patients were included, and 162 were aged older than 80 years. There was no difference in overall survival between the two groups, with a median of 39 months (95 % CI: 24-47) for those aged >80 years and 41 months (95 % CI: 31-67) for those aged 70-79 years. The same finding was observed for recurrence-free survival, with a median of 33 months (95 % CI 21-45) for patients in group-1and 34 months (95 % CI 29-39) for patients in group-2. Stratified analyses revealed a poorer prognosis for patients with locally advanced disease and combined treatment with surgery and radiotherapy for overall survival. A locally advanced stage was the only factor impacting recurrence-free survival. Furthermore, age was not considered a prognostic factor for overall or recurrence-free survival. On the other hand, the PS score, ASA score, and G8 score were significant factors.
This study revealed that advanced age was not an independent risk factor for survival and should not justify suboptimal treatment for elderly patients aged 80 years or older. Certain scores, such as the PS and G8 score, appear to be more reliable prognostic factors for oncological outcomes after treatment.
本研究旨在比较80岁及以上头颈部鳞状细胞癌患者与70 - 79岁患者的总生存期及预后因素。
进行一项2013年至2021年的回顾性研究。患者分为两组:1组年龄≥80岁,2组年龄在70至79岁之间;所有患者均被诊断为头颈部鳞状细胞癌并接受根治性治疗。
共纳入346例患者,其中162例年龄大于80岁。两组总生存期无差异,80岁以上患者的中位生存期为39个月(95%CI:24 - 47),70 - 79岁患者为41个月(95%CI:31 - 67)。无复发生存期也有相同发现,1组患者中位生存期为33个月(95%CI 21 - 45),2组患者为34个月(95%CI 29 - 39)。分层分析显示,局部晚期疾病患者以及接受手术和放疗联合治疗患者的总生存期预后较差。局部晚期是影响无复发生存期的唯一因素。此外,年龄未被视为总生存期或无复发生存期的预后因素。另一方面,PS评分、ASA评分和G8评分是显著因素。
本研究表明高龄并非生存的独立危险因素,不应成为80岁及以上老年患者接受次优治疗的理由。某些评分,如PS评分和G8评分,似乎是治疗后肿瘤学结局更可靠的预后因素。